India’s ICGEB To Work With U.S. Vaccine Center On Dengue, HIV, TB Vaccines
This article was originally published in PharmAsia News
An Indian biotech has joined with a U.S.-based vaccine center to develop vaccines against infectious diseases such as dengue, HIV and tuberculosis. India's International Centre for Genetic Engineering and Biotechnology plans to work with Emory Vaccine Center to collaborate on research on those diseases, the ICGEB's director said. ICGEB has been specializing in those diseases as well as hepatitis B and E, malaria and SARS. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.